These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
459 related articles for article (PubMed ID: 31816082)
1. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy. Kostine M; Truchetet ME; Schaeverbeke T Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii68-vii74. PubMed ID: 31816082 [TBL] [Abstract][Full Text] [Related]
2. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy. Abdel-Wahab N; Suarez-Almazor ME Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii40-vii48. PubMed ID: 31816084 [TBL] [Abstract][Full Text] [Related]
3. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint. Leipe J; Mariette X Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii49-vii58. PubMed ID: 31816078 [TBL] [Abstract][Full Text] [Related]
4. Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature. Benfaremo D; Manfredi L; Luchetti MM; Gabrielli A Curr Drug Saf; 2018; 13(3):150-164. PubMed ID: 29745339 [TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitors-related Rheumatic Diseases: What Rheumatologist Should Know? Gediz F; Kobak S Curr Rheumatol Rev; 2019; 15(3):201-208. PubMed ID: 30659547 [TBL] [Abstract][Full Text] [Related]
6. Spectrum and impact of checkpoint inhibitor-induced irAEs. Cappelli LC; Bingham CO Nat Rev Rheumatol; 2021 Feb; 17(2):69-70. PubMed ID: 33235330 [No Abstract] [Full Text] [Related]
7. Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective. Steven NM; Fisher BA Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii29-vii39. PubMed ID: 31816079 [TBL] [Abstract][Full Text] [Related]
8. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Kostine M; Finckh A; Bingham CO; Visser K; Leipe J; Schulze-Koops H; Choy EH; Benesova K; Radstake TRDJ; Cope AP; Lambotte O; Gottenberg JE; Allenbach Y; Visser M; Rusthoven C; Thomasen L; Jamal S; Marabelle A; Larkin J; Haanen JBAG; Calabrese LH; Mariette X; Schaeverbeke T Ann Rheum Dis; 2021 Jan; 80(1):36-48. PubMed ID: 32327425 [TBL] [Abstract][Full Text] [Related]
9. Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology. Cappelli LC; Shah AA; Bingham CO Rheum Dis Clin North Am; 2017 Feb; 43(1):65-78. PubMed ID: 27890174 [TBL] [Abstract][Full Text] [Related]
10. Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors. Melissaropoulos K; Klavdianou K; Filippopoulou A; Kalofonou F; Kalofonos H; Daoussis D Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32403289 [TBL] [Abstract][Full Text] [Related]
11. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. Cappelli LC; Gutierrez AK; Bingham CO; Shah AA Arthritis Care Res (Hoboken); 2017 Nov; 69(11):1751-1763. PubMed ID: 27998041 [TBL] [Abstract][Full Text] [Related]
12. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy. Narváez J; Juarez-López P; LLuch J; Narváez JA; Palmero R; García Del Muro X; Nolla JM; Domingo-Domenech E Autoimmun Rev; 2018 Oct; 17(10):1040-1045. PubMed ID: 30103042 [TBL] [Abstract][Full Text] [Related]
13. Rheumatic Complications of Immune Checkpoint Inhibitors. Ghosh N; Bass AR Rheum Dis Clin North Am; 2022 May; 48(2):411-428. PubMed ID: 35400368 [TBL] [Abstract][Full Text] [Related]
14. Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience. Mooradian MJ; Nasrallah M; Gainor JF; Reynolds KL; Cohen JV; Lawrence DP; Miloslavsky EM; Kohler MJ; Sullivan RJ; Schoenfeld SR Semin Arthritis Rheum; 2019 Jun; 48(6):1127-1132. PubMed ID: 30409415 [TBL] [Abstract][Full Text] [Related]
15. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. Mitchell EL; Lau PKH; Khoo C; Liew D; Leung J; Liu B; Rischin A; Frauman AG; Kee D; Smith K; Brady B; Rischin D; Gibson A; Mileshkin L; Klein O; Weickhardt A; Arulananda S; Shackleton M; McArthur G; Östör A; Cebon J; Solomon B; Buchanan RR; Wicks IP; Lo S; Hicks RJ; Sandhu S Eur J Cancer; 2018 Dec; 105():88-102. PubMed ID: 30439628 [TBL] [Abstract][Full Text] [Related]
16. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. Weinmann SC; Pisetsky DS Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080 [TBL] [Abstract][Full Text] [Related]
17. Toxicities associated with checkpoint inhibitors-an overview. Spiers L; Coupe N; Payne M Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii7-vii16. PubMed ID: 31816085 [TBL] [Abstract][Full Text] [Related]